Physician profile
Timothy G Tsui
NPI 1578575791
$1,479.69
in general payments reported to CMS, 2019-2025
21 companies · $553 in 2025
The $553 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.79 · 2020: $16.00 · 2021: $62.36 · 2022: $96.33 · 2023: $452 · 2024: $236 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,240.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $214.81 | 2023-2025 | |
| Exeltis, USA INC. | $183.09 | 2023-2025 | Slynd |
| Abbvie INC. | $157.33 | 2019-2023 | Lo Loestrin Fe |
| Sumitomo Pharma America, INC. | $143.78 | 2023-2025 | Myfembree, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $102.84 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $92.08 | 2025 | |
| Evofem Biosciences, INC. | $91.42 | 2021-2025 | Phexxi, Solosec, Phexx |
| Coopersurgical, INC. | $90.05 | 2020-2025 | Paragard T 380a |
| Sage Therapeutics, LLC | $65.14 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $52.84 | 2023-2024 | Twirla |
| Millicent US INC | $40.65 | 2025 | Intrarosa, Femlyv |
| Intuitive Surgical, INC. | $40.00 | 2019 | |
| Aspira Women'S Health INC | $39.93 | 2023 | Ova1 |
| Astellas Pharma US INC | $34.26 | 2025 | Veozah |
| Therapeuticsmd, INC. | $30.46 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $23.42 | 2024 | Aptima |
| Myovant Sciences INC. | $19.17 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.28 | 2023 | Quviviq |
| Alnylam Pharmaceuticals INC. | $14.60 | 2023 | Givlaari |
| Novo Nordisk INC | $13.45 | 2024 | Wegovy |
| Channel Medsystems, INC. | $12.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Tsui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.